Abstract e third joint congress of l' Association des Médicins Biochimistes du uébec (AMBQ) and the Canadian Association of Medical Biochemists (CAMB) was held this year from October 19 to 22 in Montreal. e setting was like last year the picturesque Hôtel Place d' Armes, which is situated in the historic Old Montreal district. ere were over 60 attendees comprising both Specialists and Medical residents-in-training and representing the breadth of Canada from the Atlantic to the Paci c. 
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e scienti c committee composed of Drs. Shaun Eintracht (SMBD-Jewish General Hospital ( JGH)), Brian M. Gil x (McGill University Health Centre (MUHC)), David Blank (MUHC), Elizabeth MacNamara ( JGH), and Julie StCyr (St. Mary's Hospital (SMH)) arranged a series of informative and interesting scienti c sessions.
Day 1 saw a training session for the medical residents conducted by Drs. David Keren (Wade Medical Laboratory) and Jerry Katzmann (Mayo Clinic) on testing for monoclonal gammopathies. A meeting of the Specialty Committee of the Royal College for Medical Biochemistry followed this where again the major topic of this meeting was the re-alignment of the training requirements for the specialty.
Day 2 began with the business meeting of the AMBQ. e scienti c sessions began that a ernoon with a session on "HbA1C and Diabetes Monitoring" chaired by Dr. Julie StCyr (SMH). e rst speaker, Dr. Andrew Don-Wauchope (McMaster University), in his talk "HbA1c: Truth or Politics in the published recommendations" reviewed the latest recommendations by the CSCC and CAMB and the rationale behind these recommendations. is was followed by Dr. Sylvie Bertrand (Centre Hospitalier Université Montréal), who reviewed "Insulin erapy in 2010" for adults. e morning session ended with an entirely di erent perspective with Dr. Constatin Polychronakos's (MUHC) presentation "HbA1c and the Management of Type , and Pierre Leclerc (Centre Hospitalier Université Laval) had the "di cult" task of awarding prizes to the best oral presentations. e winners this year were Dr. Ann Ganglo (CHUQ) for the oral presentation entitled "A novel mutation of ApoB in a member of a French Canadian family with hypobetalipoproteinemia " and Dr. Ahlem Chouiali for the oral presentation entitled "Une Néoplasia Tellement Atypique". e scienti c portion of the conference ended with a most comprehensive presentation on analytical strategies for detection of "doping" in sports by Dr. Christine Ayotte (INRS-Institute Armand-Frappier). Dr. Ayotte reminded us that there is a continual evolutionary struggle between those developing new doping agents and those trying to detect these agents.
e day and the congress ended with a business meeting of the CAMB chaired by the president, Dr. Elizabeth MacNamara. A new executive was elected: Dr. Dr. Andrew DonWauchope (McMaster U. Health Sciences Centre, vicepresident), Dr. Brian M. Gil x (MUHC, secretary-treasurer), and Dr. Pierre Douville (CHUS, councilor). Dr. Andre Mattman (BCCWHC), Dr. Yves Guigère (CHUQ, councilor) and Dr. John Heathcote (Vancouver, councilor) continued as councilors.
We all look forward to next year's combined meeting, which is slated to take place in uebec City in October, 2011. Introduction: We report the case of a 27 year-old woman diagnosed with hypobetalipoproteinemia during her rst year of life. Her parents are distant cousins and have 12 children, of whom 3 (the proband and 2 younger brothers) have con rmed hypobetalipoproteinemia.
Une néoplasie tellement atypique…
Observations: Clinical data -Signs and symptoms at diagnosis included diarrhea and acanthocytosis on the blood smear. Vitamins A, D and E were started in childhood, but compliance has been uncertain. Supplements and medical follow-up were stopped between ages 18 and 25 years. e patient denies any neurological symptoms other than diminished visual acuity in the le eye. Genetic -A novel homozygous coding mutation in APOB (G275, T276V>300X) was identi ed.
e DNA sequence encodes a severely truncated ApoB protein (300 aa instead of 4536 aa, 7% of the normal length).
Conclusion:
We report a French Canadian patient with familial hypobetalipoproteinemia characterized by undetectable levels of apoB secondary to a homozygous early stop codon.
Métabolisme du manganèse au cours de la nutrition parentérale à long terme Le principal mécanisme de régulation de l'homéostasie du manganèse est la diminution de l'absorption intestinale, l'administration parentérale contourne ce mécanisme. De plus l'élimination se fait essentiellement par le système hépatobiliaire, qui est souvent dé-térioré chez les patients sous nutrition parentérale. L'ensemble de ces facteurs entrainerait une élévation des concentrations du manganèse dans le sang avec accumulation au niveau du cerveau et neurotoxicité.
Résultats: Une surveillance régulière est recommandée. Les concentrations dans le sang total sont plus précises et corrèlent avec les changements de l'intensité du signal en imagerie par résonnance magnétique du cerveau, cependant l'association entre ces mesures et les symptômes cliniques n'est pas établie.
Les recommandations pour la suplémentation des éléments traces requiert une révision a n d'individualiser les formules de dosages en nutrition parentérale à long terme.
Une surveillance fréquente pour détecter une accumulation du manganèse dans le cerveau est recommandée.
Conclusion: Avec l'évidence de la croissance de toxicité au manganèse associé à la nutrition parentérale et la présence de cas très rares de dé cit, la suplémentation systématique en manganèse chez les patients en nutrition parentérale à long terme ne serait pas néces-saire.
E ects of blood and blood product transfusion on newborn metabolic screening for biotinidase de ciency Huston, A. and Bamforth, F.
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB Background: Biotinidase de ciency screening is included in many newborn screening programs. Blood or blood products transfused prior to sample collection potentially may cause a false negative newborn screen in a newborn with biotinidase de ciency.
Objectives: To evaluate biotinidase activity in blood products typically transfused in a neonate and to assess likelihood of a false negative newborn screen.
Materials and methods:
Biotinidase activity was measured semi-quantitatively by incubating dried blood spots overnight with Nbiotinyl-PABA, and measuring the released PABA colorimetrically. Biotinidase activity was measured in the following products: packed red cells, platelets (pooled and apheresis), human albumin 5% and 20% USP (Plasbumin ® ) and frozen plasma. If biotinidase activity was present, the product was mixed with biotinidase de cient blood (prepared by heat inactivation of enzyme in serum and reconstituting with washed red blood cells) to simulate typical transfusion volumes (Canadian Blood Services guidelines) for a 2.72 Kg neonate.
Results: Prepared biotinidase de cient blood showed no biotinidase activity. Biotinidase activity was absent in packed red cells and albumin (5% and 20%) but present in platelets and frozen plasma.
e interpretation of the biotinidase screen a er simulated transfusion of platelets and frozen plasma to biotinidase de cient blood was as follows: platelets ≤10 mL/Kg body weight: Profound de ciency; platelets ≥15 mL/Kg: Partial de ciency; frozen plasma ≤5 mL/Kg: Partial de ciency; frozen plasma ≥10 mL/ Kg: Normal biotinidase activity. Determination of trimester-speci c refrefnce ranges for thyroid function in pregnant women: are they necessary?
Amari, M.A. , Giguère, Y., et Girouard, J.
Centre Hospitalier Université Laval, uébec, QC Background: yroid disease can a ect pregnancy and adequate thyroid function is important for fetal development as well. To ensure that thyroid status is correctly evaluated in pregnant woman, the reference range against which tests results are compared must be optimally de ned for the stage of pregnancy.
Study design: e project aimed to de ne reference ranges for the pregnant women population followed at the CHUQ. ree subgroups of pregnant women based on gestational age in weeks were tested: [14-16] [24-28] and [28] [29] [30] [31] [32] [33] [34] [35] [36] . A 4 th group that will include only rst trimester [9-13] is currently being set up. Women in each group were tested anonymously for TSH, Free T4 and Total T3, and Anti-TPO on Roche Modular system.
Results: 13% of women were excluded for the presence of elevated anti-TPO antibodies. Using percentiles 2.5 and 97.5 we determined reference range for TSH. For the FT4 and TT3, two sets of reference ranges were calculated: one based on 2.5th and 97.5th and the other based on entire range of those having TSH within determined reference range. e results are shown below.
e upper reference limit for TSH is lower earlier in pregnancy. FT4 reference limits dri towards lower values as pregnancy progresses.
Conclusion: is suggests the need of trimester-speci c reference ranges for thyroid function tests in pregnancy to optimize pregnancy outcome and healthcare service use.
Impact du test statistique dans la comparaison d'échantillons indépendants
Zenagui, S 1 . et Larivière, F 2 .
1 Université de Montréal. 2 Centre Hospitalier de l'Université de Montréal, Montréal, QC Objectifs : La comparaison de deux échantillons indépendants soulève souvent le problème du choix du test statistique optimal. Les recommandations usuelles discutent rarement l'impact que peut avoir le choix du test sur sa performance. Nous avons donc voulu explorer les conséquences du choix du test statistique sur la valeur réelle du niveau de signi cation par rapport à sa valeur nominale.
Méthodes : Le logiciel R a été utilisé pour e ectuer de l'échantillonnage multiple sur des populations de distribution symétrique et asymétrique. Les valeurs réelles du niveau de signi cation des 3 tests statistiques suivants, t de Student, Welch et Wilcoxon-Mann-AMBQ-CAMB 2010
